TY - JOUR
T1 - Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients
AU - Nguyen, Q.
AU - Champlin, R.
AU - Giralt, S.
AU - Rolston, K.
AU - Raad, I.
AU - Jacobson, K.
AU - Ippoliti, C.
AU - Hecht, D.
AU - Tarrand, J.
AU - Luna, M.
AU - Whimbey, Estella
PY - 1999
Y1 - 1999
N2 - To assess the impact of antiviral prophylaxis during the first 3 months after transplantation on the frequency, timing, and outcome of cytomegalovirus (CMV) pneumonia during the first year, 541 adult allogeneic blood and marrow transplant recipients were evaluated. Thirty-four patients (6.3%) developed 35 episodes of CMV pneumonia at a mean of 188 days after transplantation, with an associated mortality rate of 76%. Twenty-six episodes (74%) occurred late (after day 100). Of the patients with late CMV pneumonia almost all (92%) had chronic graft vs. host disease or had received T cell-depleted transplants. Fourteen late CMV pneumonias (54%) were associated with serious concurrent infections, and 100% of these episodes were fatal. In conclusion, although the frequency of CMV pneumonia in the early posttransplantation period may be substantially reduced by prophylaxis, CMV continues to be a major cause of morbidity and mortality in the late period. Some subsets of patients need more prolonged surveillance and prophylaxis and/or preemptive therapy.
AB - To assess the impact of antiviral prophylaxis during the first 3 months after transplantation on the frequency, timing, and outcome of cytomegalovirus (CMV) pneumonia during the first year, 541 adult allogeneic blood and marrow transplant recipients were evaluated. Thirty-four patients (6.3%) developed 35 episodes of CMV pneumonia at a mean of 188 days after transplantation, with an associated mortality rate of 76%. Twenty-six episodes (74%) occurred late (after day 100). Of the patients with late CMV pneumonia almost all (92%) had chronic graft vs. host disease or had received T cell-depleted transplants. Fourteen late CMV pneumonias (54%) were associated with serious concurrent infections, and 100% of these episodes were fatal. In conclusion, although the frequency of CMV pneumonia in the early posttransplantation period may be substantially reduced by prophylaxis, CMV continues to be a major cause of morbidity and mortality in the late period. Some subsets of patients need more prolonged surveillance and prophylaxis and/or preemptive therapy.
UR - http://www.scopus.com/inward/record.url?scp=0033013624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033013624&partnerID=8YFLogxK
U2 - 10.1086/515146
DO - 10.1086/515146
M3 - Article
C2 - 10194088
AN - SCOPUS:0033013624
SN - 1058-4838
VL - 28
SP - 618
EP - 623
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -